Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.39 |
| ▸ | NAAA | Q02083 | 2/20 | 0.38 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.38 |
| ▸ | BCL2 | P10415 | 1/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.38 |
| ▸ | THRA | P10827 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MLYCD | O95822 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3545762 | 0.83 | THRA (0.41) | CA2L3MBTL1MAPK9MAPK10HDAC3 | |
| SCHEMBL11928842 | 0.81 | CA2 (0.37) | CA2L3MBTL1MAPK9MAPK10HDAC3 | |
| SCHEMBL3547492 | 0.80 | MEN1 (0.54) | CA2L3MBTL1MAPK9MAPK10HDAC3 | |
| SCHEMBL3545420 | 0.80 | MEN1 (0.50) | CA2L3MBTL1MAPK9MAPK10HDAC3 | |
| SCHEMBL5016503 | 0.79 | MAPK9 (0.39) | CA2MAPK9MAPK10HDAC3HDAC1 | |
| SCHEMBL3540537 | 0.77 | KMT2A (0.47) | CA2MAPK9MAPK10HDAC3HDAC1 | |
| SCHEMBL5016505 | 0.77 | MAPK9 (0.37) | CA2MAPK9MAPK10HDAC3HDAC1 | |
| SCHEMBL3541063 | 0.76 | MEN1 (0.43) | CA2L3MBTL1MAPK9MAPK10HDAC3 | |
| SCHEMBL3479954 | 0.75 | MAPK9 (0.57) | MAPK9MAPK10BCL2BCL2L1MEN1 | |
| SCHEMBL3479861 | 0.75 | MAPK9 (0.57) | MAPK9MAPK10BCL2BCL2L1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1409483-B1 | ARYLSULFONAMIDE DERIVATIVES AS C-JUN-N-TERMINAL KINASES (JNK'S) INHIBITORS | SERONO LAB (CH) | 2008-12-31 | — | — | EP | claimed |
| EP-1409483-A1 | ARYLSULFONAMIDE DERIVATIVES AS C-JUN-N-TERMINAL KINASES (JNK'S) INHIBITORS | Applied Research Systems ARS Holding N.V. (AN) | 2004-04-21 | — | — | EP | claimed |
| WO-2003010164-A1 | ARYLSULFONAMIDE DERIVATIVES AS C-JUN-N-TERMINAL KINASES (JNK'S) INHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-02-06 | — | — | WO | claimed |
| US-7683078-B2 | Arylsulfonamide derivatives as C-Jun-N-Terminal Kinases (JNK's) inhibitors | LABORATOIRES SERONO S.A. (CH) | 2010-03-23 | — | — | US | disclosed |
| US-20100029719-A1 | ARYLSULFONAMIDE DERIVATIVES AS C-JUN-N-TERMINAL KINASES (JNK'S) INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2010-02-04 | — | — | US | disclosed |
| EP-1409483-B1 | ARYLSULFONAMIDE DERIVATIVES AS C-JUN-N-TERMINAL KINASES (JNK'S) INHIBITORS | SERONO LAB (CH) | 2008-12-31 | — | — | EP | disclosed |
| US-20040248886-A1 | Pharmaceutically active sulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors | MERCK SERONO SA (CH) | 2004-12-09 | — | — | US | disclosed |
| EP-1409483-A1 | ARYLSULFONAMIDE DERIVATIVES AS C-JUN-N-TERMINAL KINASES (JNK'S) INHIBITORS | Applied Research Systems ARS Holding N.V. (AN) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003010164-A1 | ARYLSULFONAMIDE DERIVATIVES AS C-JUN-N-TERMINAL KINASES (JNK'S) INHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248886-A1 | Pharmaceutically active sulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors | MAPK1, MAPK3, MAP3K2 | CA2 1188/4885L3MBTL1 4670/4885MAPK9 28/4885 |
| US-20100029719-A1 | ARYLSULFONAMIDE DERIVATIVES AS C-JUN-N-TERMINAL KINASES (JNK'S) INHIBITORS | MAPK1, MAPK3, MAP3K2 | CA2 2814/4885L3MBTL1 4083/4885MAPK9 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.